75% of biopharma leaders expect partnering and M&A appetite to increase over the next 12 months, none expect a decline 69% expect access to capital to improve, yet 79% identify investor risk aversion as the biggest constraint on biotech investment 52% say US policy uncertainty has made Europe more attractive to build and partner in, […]
Appointment brings extensive experience spanning drug discovery, translational medicine, clinical development and scientific leadership HORGEN, Switzerland, October 1, 2026 – Numab Therapeutics (“Numab”), a biotechnology company advancing a proprietary pipeline of multispecific antibodies in immunology and oncology, today announced the appointment of Rajesh Chopra, M.D., PhD, as Chief Scientific Officer. Read more…
San Francisco, California – Yavne, Israel – July 14th, 2026 – Genopore, the next-generation proteomics company developing the first semiconductor based optical nanopore technology platform with AI/ML analysis for direct single protein molecule identification and digital quantification, today announced the appointment of life science leader Rey Mali as its new Chief Executive Officer, with immediate […]
FB301 was safe and well tolerated in healthy female subjects, with all primary and secondary endpoints met Clinically meaningful microbiome modulation observed, including significant improvement up to 6-month follow-up Results support progression into Phase 2, with FDA IND clearance granted in the US and CTA approved in Germany Copenhagen, Denmark and Boston, Massachusetts, 16 April […]
Dr. Thomas L. F. Montgomery Andresen joins from T-Cypher Bio Follows breakthrough non-human primate data demonstrating deep B-cell depletion without cytokine release Commit is poised to nominate its first two clinical development candidates later in 2026 COPENHAGEN, Denmark — March 11, 2026 — Commit Biologics (“Commit”), a biotechnology company pioneering complement system activation and backed […]
